USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth

Participants:

Mansa Shroff Director of Business Dev & Chief of StaffWKD.SMRT
Mansa Shroff
Director of Business Dev & Chief of StaffWKD.SMRT
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC
Andy Oho Assoc. Director Digital HealthBoehringer Ingelheim International GmbH
Andy Oho
Assoc. Director Digital HealthBoehringer Ingelheim International GmbH
Celine Vignal Co-FounderNeurodigitX
Celine Vignal
Co-FounderNeurodigitX
Claire Donnelly Head of Medical PartnershipsHappitech
Claire Donnelly
Head of Medical PartnershipsHappitech
Gabriele Tundo PartnerPlexus Ventures
Gabriele Tundo
PartnerPlexus Ventures
Gregoire Guillet Chief Business and Value OfficerWeHealth Digital Medicine
Gregoire Guillet
Chief Business and Value OfficerWeHealth Digital Medicine
Jim Diefenbach Senior Vice President of Global SalesODAIA
Jim Diefenbach
Senior Vice President of Global SalesODAIA
Jo Masterson CEO2Morrow, Inc.
Jo Masterson
CEO2Morrow, Inc.
Jyri Yli-Villamo Head of Pharma Global Strategic PartnershipsKaiku Health
Jyri Yli-Villamo
Head of Pharma Global Strategic PartnershipsKaiku Health
KM
Kira Menshikova Digital health managerBionorica SE
KM
Kira Menshikova
Digital health managerBionorica SE
Marcus Bates VP Business DevelopmentAptar Digital Health
Marcus Bates
VP Business DevelopmentAptar Digital Health
Thyago Ohana Digital Strategy & Capabilities LeadUCB Pharma
Thyago Ohana
Digital Strategy & Capabilities LeadUCB Pharma
Tracy Lahey Strategy & Business Development ManagerAmgen
Tracy Lahey
Strategy & Business Development ManagerAmgen

About this Meeting

Digital tools are becoming increasingly used across the Pharmaceutical industry, Digital Therapeutics (DTx) being an element of Pharma digital transformation, feeding into many companies overall strategic plans. This meeting deep dives into DTx-Pharma partnerships and it focuses on how to monetize DTx within the traditional pharmaceutical business model. Join us in this informal conversation with leaders of the industry where we will speak on topics like: 

  •  Drivers for both DTx and pharma companies for partnering up 
  •  How to monetize DTx in a traditional pharma business (ROI)? 
  •  Most pharma-DTx collaborations have been DTx-drug combinations as opposed to standalone therapies; will this change in the next few years?  
  •  From an organizational perspective, what are the key changes pharma needs to do to successfully integrate DTx in their business model?